Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation
Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary Scorpions® technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics (IVD) field. Epigenomics intends to use this technology both in certain research kits as well as potentially in its cancer specialty diagnostics products. DxS in return receives an option for a worldwide non-exclusive license and further options to certain Epigenomics IP covering the use of Scorpions® technology for DNA methylation applications. Both Epigenomics and DxS have acquired options to sub-licensing rights for the respective technologies.
Further details and financial terms of the agreement were not disclosed.
Most read news
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.